•
Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed that it has received tacit clinical approval from the National Medical Products Administration (NMPA) for its drug candidate HF50. This T-cell redirecting antibody fragment-anchored liposomes (TRAFsomes) product will be tested in clinical trials for HER-2…
•
The National Medical Products Administration (NMPA) of China has officially approved pretomanid, developed by Shenyang Hongqi Pharmaceutical Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196). This approval marks a significant advancement in the treatment of drug-resistant tuberculosis (TB) patients. Innovative Mechanism of Action Pretomanid is…
•
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a supplementary exclusive distribution and co-promotion agreement with UK pharmaceutical major GlaxoSmithKline (GSK, NYSE: GSK), optimizing and adjusting the original deal concerning the recombinant herpes zoster vaccine. The revised agreement removes the original minimum procurement amount, allowing Zhifei Bio…
•
GSK plc (NYSE: GSK) has announced a new partnership with Danish biotech firm Muna Therapeutics, following recent collaborations with Sino-US Duality Biologics and US biotech Rgenta Therapeutics. This latest alliance aims to identify and validate novel drug targets for the treatment of Alzheimer’s disease, leveraging insights from Muna’s MiND-MAP platform,…
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received breakthrough therapy designation (BTD) from the National Medical Products Administration of China for its pipeline candidate, SHR-A2102. The designation is in recognition of the molecule’s potential in treating locally advanced or metastatic urothelial carcinoma in patients who…
•
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the US Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for its drug Columvi (glofitamab). Roche is seeking FDA approval for the use of Columvi in combination with gemcitabine and oxaliplatin (GemOx) for the…
•
Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced its intention to sell all holdings in Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. to JKI, a company established by a fund managed and operated by J-Will. This strategic move aligns with Teva’s Pivot to…
•
China-based ophthalmic medical device manufacturer, Eyebright Medical Technology Co., Ltd (SHA: 688050), has announced plans to raise up to RMB 300 million (USD 41.3 million) through a private placement of 3,787,878 shares. The capital raised will be allocated towards the construction project of a contact lens and injection mold processing…
•
US-based contract development and manufacturing organization (CDMO) Cambrex has reached an agreement with Eli Lilly & Co., (NYSE: LLY), to enhance the clinical development capabilities for the US giant’s biotech collaborators. This partnership aims to provide a comprehensive suite of services to support early-stage biotech innovation. Cambrex’s Role in Lilly…
•
US-based Dewpoint Therapeutics Inc. has entered into a strategic partnership with Japan-headquartered Mitsubishi Tanabe Pharma Corporation (MTPC) to enhance the development of Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS). This collaboration aims to address the mislocalization of the TAR DNA-binding protein 43 (TDP-43), a…
•
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has reported receiving a new indication approval from the US Food and Drug Administration (FDA) for its programmed death-ligand 1 (PD-L1) inhibitor, Imfinzi (durvalumab). The approval is for the use of Imfinzi in treating adult patients with limited-stage small cell lung cancer (LS-SCLC)…
•
US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the expansion of its manufacturing facility in Kenosha County, Wisconsin, with a substantial capital investment of USD 3 billion. This significant expansion, acquired earlier this year, is part of Lilly’s strategic plan to enhance its global parenteral (injectable) product…
•
US biotech company Amgen (NASDAQ: AMGN) has announced plans to construct a second drug substance manufacturing facility in Holly Springs, North Carolina, raising its total biomanufacturing investment in the region to USD 1.5 billion. This new plant, costing USD 1 billion, follows Amgen’s previously announced commitment of USD 550 million…
•
US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the Phase III MOVE-NOW study for its oral antiviral COVID-19 medicine, Lagevrio (molnupiravir), in adults with COVID-19 who are at high risk for disease progression. This trial marks a significant step in the ongoing development and…
•
China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated that the Category 1 drug RG002, developed by Suzhou-based mRNA therapeutics company RinuaGene, has been approved for clinical study in cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) associated with human papillomavirus (HPV) 16 and/or…
•
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has released its financial results for the third quarter of 2024. The company reported Q3 revenues of RMB 128.6 million (USD 18.3 million), marking a year-on-year (YOY) increase of 0.8%. Research and development (R&D) expenses saw a significant decline of 41.3% YOY,…
•
US-based Novavax, Inc. (NASDAQ: NVAX) has reached an agreement to sell its manufacturing facility located in Bohumil, Czech Republic, to Denmark-based Novo Nordisk A/S (NYSE: NVO) for a total consideration of USD 200 million. The transaction involves the transfer of assets, including a 150,000-square foot state-of-the-art recombinant protein manufacturing facility,…
•
US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has revealed a positive readout from the open-label, randomized Phase III SURMOUNT-5 study. The study assessed the weight loss effects of Zepbound (tirzepatide) compared to Wegovy (semaglutide) in adult patients with obesity or overweight, who have at least one weight-related medical…
•
Sino-US biotech company Phanes Therapeutics Inc. has announced that it has received another Fast Track designation from the US Food and Drug Administration (FDA) for its bispecific antibody (bsAb) PT217. This designation is specifically for the treatment of patients with metastatic de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). Earlier…
•
The National Medical Products Administration (NMPA) in China has indicated on its website that CGeneTech (Suzhou, China) Co., Ltd.’s Category 1 drug, cetagliptin, has been granted marketing approval. This DPP-4 inhibitor is intended to improve blood sugar control in adult patients with type 2 diabetes (T2D). Phase III Clinical Trial…